Join +750K new investors every month who copy stock picks from billionaire's portfoliosSign Up Free

Vera Therapeutics Shares Plunge After Mixed Data From Rare Kidney Disease Study

Published 04/01/2023, 11:52
Updated 04/01/2023, 13:10
© Reuters.  Vera Therapeutics Shares Plunge After Mixed Data From Rare Kidney Disease Study
VERA
-

Benzinga -

  • Vera Therapeutics Inc (NASDAQ: VERA) unveiled topline data from Phase 2b ORIGIN trial of atacicept in patients with immunoglobulin A nephropathy (IgAN).
  • The trial evaluated three doses of atacicept - 150 mg, 75 mg, and 25 mg, versus the placebo.
  • A pooled group of IgAN patients receiving either a 75 mg or 150 mg dose of atacicept saw a 31% mean reduction from baseline in proteinuria, protein levels in the urine, compared to 7% in the placebo group at 24 weeks, meeting the primary endpoint.
  • While the 25 mg and 75 mg dose groups failed to meet statistical significance, the 150 mg group showed a 33% reduction.
  • The company says a trend towards further reductions in proteinuria was observed in the all-atacicept group versus placebo, with 38% of patient data available at Week 36.
  • Atacicept was generally well-tolerated, with serious treatment-emergent adverse events occurring in 2% of atacicept patients and 9% of patients in the placebo arm.
  • Vera plans to advance atacicept into pivotal Phase 3 development in the first half of 2023.
  • Upon completing the 36-week blinded treatment period, all patients are offered open-label atacicept 150 mg for an additional 60 weeks.
  • After the above data, the company plans to take the 150 mg dose forward into planned Phase 3 pivotal trial.
  • Price Action: VERA shares are down 62.95% at $6.78 during the premarket session on the last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.